Group 1 - Company Antu Biology (603658.SH) announced that its wholly-owned subsidiary Zhengzhou Yimeinuo Biotechnology Co., Ltd. and its secondary subsidiary Zhengzhou Biaoyuan Biotechnology Co., Ltd. have recently received the "High-tech Enterprise Certificate" from the Henan Provincial Department of Science and Technology, Henan Provincial Department of Finance, and the State Taxation Administration of Henan Province [1] - The certificate numbers are GR202541002114 and GR202541001628, with both issued on November 4, 2025, and valid for three years [1] - This recognition is a renewal of the previous high-tech enterprise certification, allowing the subsidiaries to continue enjoying tax benefits under the national policy for high-tech enterprises, specifically a corporate income tax rate of 15% from 2025 to 2027 [1]

Group 1 - AnTu Biologics announced the receipt of medical device registration certificates from the National Medical Products Administration and the Henan Provincial Medical Products Administration for products including the "Respiratory Syncytial Virus Antigen Test Kit" [1] - The announcement highlights the company's progress in expanding its product offerings in the medical device sector [1] Group 2 - A new type of chip has been developed in China, which can bypass the limitations imposed by lithography machines [1] - This new chip supports AI training and embodied intelligence and can be mass-produced using mature processes of 28 nanometers and above [1]

关于公司及二级子公司获得医疗器械注册证的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 郑州安图生物工程股份有限公司（以下简称"公司"或"安图生物"）及二 级子公司郑州标源生物科技有限公司（以下简称"郑州标源"）于近日收到国家 药品监督管理局、河南省药品监督管理局颁发的医疗器械注册证，具体如下： | 编号 | 产品名称 | 注册证编号 | 注册证 | 预期用途 | 所属 | | --- | --- | --- | --- | --- | --- | | | | | 有效期 | | 公司 | | 1 | 呼吸道合胞病毒抗原检 测试剂盒（磁微粒化学 | 国械注准 20253402552 | 5 年 | 本产品用于定性检测人鼻拭子和口 咽拭子样本中的呼吸道合胞病毒抗 | | | | 发光法） | | | 原（RSV Ag）。 | | | 2 | 腺病毒抗原检测试剂盒 （磁微粒化学发光法） | 国械注准 20253402666 | 5 年 | 本产品用于定性检测人鼻拭子和口 咽拭子样本中的腺病毒抗原（ADV Ag）。 | | | ...

Group 1 - The Henan Health Industry Development Conference was held in Zhengzhou, focusing on the integration of medical research and industry, aiming to enhance the health industry brand in Henan and support its integration into the national market [1][3] - The "National Artificial Intelligence Application Pilot Base (Medical Field)" was inaugurated, designed to provide comprehensive pilot services for medical AI products, accelerating the industrialization of innovative results [2] - The conference attracted hundreds of guests from various sectors, including government, industry, academia, and investment, to discuss development paths and consolidate industry collaboration [1][2] Group 2 - A signing ceremony took place, resulting in agreements between Zhengzhou Airport Economic Zone and 13 industry projects, including partnerships with major companies like MaiSheng Medical and Guojian Zhongyuan [2] - Companies such as Zhengzhou Antu Bioengineering Co., Ltd. and others expressed their commitment to expanding their operations in Henan, highlighting the region's unique industrial advantages and policy resources [2] - The Zhengzhou Airport Economic Zone plans to establish a regular mechanism for medical and industrial collaboration, aiming to drive innovation and transformation in the health industry [3]

Investment Rating - The industry rating is "Overweight" and has been maintained from the previous rating [4] Core Insights - The global IVD market is projected to grow from USD 66.7 billion in 2018 to USD 186.1 billion by 2030, with a CAGR of 8.9% [12] - The Chinese IVD market is expected to increase from RMB 71.3 billion in 2018 to RMB 415.2 billion by 2030, with a CAGR of 15.8%, significantly outpacing the global average [13] - The immunodiagnostics market in China is experiencing rapid growth, with a market size increase from RMB 37.3 billion in 2021 to RMB 50.3 billion in 2023, reflecting a CAGR of 16.13% [16] - The POCT market is also expanding quickly, growing from RMB 11.2 billion in 2021 to RMB 16 billion in 2023, with a CAGR of 19.52% [20] - The molecular diagnostics market, despite a decline from RMB 23.1 billion in 2021 to RMB 14.8 billion in 2023, still shows potential with a market size exceeding RMB 10 billion when excluding emergency-related factors [25] Summary by Sections IVD Market Outlook - The IVD industry began in the 1950s and has seen significant growth due to advancements in medical technology and increasing health demands [11] - The Chinese IVD market has diversified into various diagnostic technologies, including biochemical, immunological, POCT, molecular, and pathological diagnostics [15] Immunodiagnostics Market - The immunodiagnostics market is the largest segment in China's IVD market, accounting for over 40% in 2023 [15] - The market is expected to face some deceleration due to price reductions from centralized procurement policies [16] Biochemical Diagnostics Market - The biochemical diagnostics market in China grew from RMB 17.1 billion in 2021 to RMB 19 billion in 2023, with a CAGR of 5.41% [19] - Domestic products dominate this market with over 70% market share [19] POCT Market - The POCT market is driven by convenience and increased demand for home testing, growing from RMB 11.2 billion in 2021 to RMB 16 billion in 2023 [20] Molecular Diagnostics Market - The molecular diagnostics market has faced challenges, declining from RMB 23.1 billion in 2021 to RMB 14.8 billion in 2023, primarily due to reduced demand post-pandemic [25] Pathogen Microbiology Market - The pathogen microbiology diagnostics market in China is projected to grow from RMB 16.82 billion in 2018 to RMB 90.27 billion by 2030, with a CAGR of 15.0% [30]

责任编辑：小浪快报 资料显示，郑州安图生物工程股份有限公司位于河南省郑州经济技术开发区经开第十五大街199号，成 立日期1999年9月15日，上市日期2016年9月1日，公司主营业务涉及体外诊断试剂及仪器的研发、生产 和销售。主营业务收入构成为：试剂86.63%，仪器10.99%，其他1.40%，维保收入0.98%。 截至9月30日，安图生物股东户数3.40万，较上期减少0.58%；人均流通股16816股，较上期增加0.58%。 2025年1月-9月，安图生物实现营业收入31.27亿元，同比减少7.48%；归母净利润8.60亿元，同比减少 10.11%。 分红方面，安图生物A股上市后累计派现40.46亿元。近三年，累计派现17.94亿元。 机构持仓方面，截止2025年9月30日，安图生物十大流通股东中，中庚价值先锋股票（012930）位居第 三大流通股东，持股783.61万股，相比上期减少141.73万股。香港中央结算有限公司位居第四大流通股 东，持股714.85万股，相比上期增加421.43万股。华宝中证医疗ETF（512170）位居第五大流通股东， 持股483.37万股，相比上期减少90.91万股。大成睿 ...

郑州安图生物工程股份有限公司 证券代码：603658 证券简称：安图生物 公告编号：2025-084 关于使用闲置募集资金进行现金管理 赎回及进展的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 已履行及拟履行的审议程序 郑州安图生物工程股份有限公司（以下简称"公司"）于 2025 年 12 月 9 日召开第五届董事会第九次会议，审议通过了《关于使用闲置募集资金进行 现金管理的议案》，同意公司在确保不影响募集资金项目建设和募集资金使 用的情况下，公司拟分别使用不超过 1.4 亿元公开发行可转换公司债券闲置 募集资金和不超过 15.4 亿元非公开发行股票闲置募集资金进行现金管理，分 别用于购买产品期限或剩余期限不超过 12 个月的结构性存款、大额存单、 国债逆回购、券商收益凭证、券商理财产品等安全性高、流动性好的保本型 产品。在上述额度范围内，资金可在 12 个月内滚动使用。具体内容详见公 司于 2025 年 12 月 10 日在上海证券交易所网站（www.sse.com.cn）披露的《安 图生物关于使用闲 ...

Core Viewpoint - Antu Biology (603658) has launched the Si kun series of gene sequencers, marking a significant milestone in its path of independent innovation and providing a high-cost performance, open-compatible, and self-controlled domestic option in the gene detection market [3]. Group 1: Product Launch - The Si kun series includes three models: Si kun 2000, Si kun 1000, and Si kun 500, designed to meet the differentiated throughput needs of various medical institutions [3]. - The sequencers are applicable in clinical scenarios such as tumor gene testing, genetic disease screening, and pathogen monitoring [3]. - Key optical systems, biochemical enzyme materials, base reagents, and core algorithms related to the sequencers have been fully self-developed, eliminating reliance on imported supply chains [3]. Group 2: Market Impact - The launch of the Si kun series fills a product gap for Antu Biology in the gene detection field [3]. - The new products represent a substantial breakthrough in constructing a comprehensive gene detection solution that includes instruments, reagents, and software [3].

2025年12月15日，郑州安图生物工程股份有限公司通过中国国际贸易"单一窗口"，成功自助打印出带有 海关电子签章的报关单证。这是河南省首份通过自助方式打印的报关单证，标志着海关报关单证及电子 数据自助查询打印服务正式落地，外贸企业迎来"足不出户、随时获取"的单证管理新体验。 郑州海关近年来持续推进智慧海关建设和"智关强国"行动，此次报关单证自助打印服务的全面落地，正 是以科技创新推动服务智能化、便捷化的缩影。该项措施显著提升了贸易便利化水平，是深化"放管 服"改革、优化跨境贸易营商环境的关键一环。下一步，郑州海关将继续聚焦企业需求，持续优化报关 单证管理模式，加强政策宣传与实操指导，降低外贸企业制度性交易成本，为河南打造高水平开放型经 济、推动外贸高质量发展注入新动能。 （原载于2025年12月17日《河南日报》2版） 这项便利化措施源于海关总署在全国推广的报关单证及电子数据自助查询打印服务。自2025年12月15日 起，该服务已在全国海关全面实施。据郑州海关统计处负责人介绍，企业只需登录中国国际贸易"单一 窗口"标准版网站，进入相应模块即可操作，单次查询时间跨度不超过3个月。普通企业每日每次最多可 查询5 ...

"过去打印盖章报关单，得跑海关业务现场，现在只需在电脑前点几下，20分钟左右就能批量完 成，省时又省力！"安图生物公司国际商务部经理李畅感慨道。该公司主要出口体外诊断试剂与仪器， 以往为评估货物出口情况，需派员赴多个申报地海关调取打印纸质报关单证，流程耗时长达2至4个工作 日。如今，通过"单一窗口"的"报关单证自助查询打印"模块，企业可随时查询、下载并打印与海关现场 盖章单证具有同等效力的电子档案，实现了数据获取的即时化、精准化和便捷化。 据了解，此次自助打印服务的全面落地，是郑州海关以科技创新推动服务智能化、便捷化的缩影。 近年来，郑州海关持续推进智慧海关建设和"智关强国"行动，助力全省跨境贸易营商环境不断优化、贸 易便利化水平不断提升。 12月15日，在郑州海关所属郑州新区海关的指导下，郑州安图生物工程股份有限公司通过中国国际 贸易"单一窗口"，成功自助打印出带有海关电子签章的报关单证。这是我省首份通过自助方式打印的报 关单证，标志着海关报关单证及电子数据自助查询打印服务在全省正式落地，外贸企业迎来"足不出 户、随时获取"的单证管理新体验。 这项便利化措施源于海关总署在全国推广的报关单证及电子数据自助查询 ...